Ivo Abraham

18PUBLICATIONS
52CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsSurgeryHealth economicsInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Oct 03, 2024
Budget impact analysis of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer.

Ivo Abraham, Matthias Calamia, Nimer Alkhatib

|Jul 17, 2024
Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer.

Karen MacDonald, Marc Pondel, Ivo Abraham

|Jul 17, 2024
Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.

Ivo Abraham, Matthias Calamia, Nimer Alkhatib

|Apr 27, 2024
Polytomous Rasch Analyses of Surgeons' Decision-Making on Choice of Procedure in Endoscopic Lumbar Spinal Stenosis Decompression Surgeries.

Kai-Uwe Lewandrowski, Rossano Kepler Alvim Fiorelli, Mauricio G Pereira

|Mar 15, 2024
Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.

Karen MacDonald, Marc Pondel, Ivo Abraham

|Jan 26, 2024
What to Expect in 2024: Important Health Economics and Outcomes Research (HEOR) Trends.

Ivo Abraham, Mickael Hiligsmann, Kenneth K C Lee

Pageof 3

Frequent Collaborators

4 joint publications

Karen MacDonald

4 joint publications

Kai-Uwe Lewandrowski

4 joint publications

Marc Pondel

3 joint publications

Nicola Montemurro